title: Pyrosequencing to detect mutations in FKS1 that confer reduced echinocandin susceptibility in Candida albicans.
abstract: Pyrosequencing was compared to Sanger dideoxy sequencing to detect mutations in FKS1 responsible for reduced echinocandin susceptibility in Candida albicans. These methods were in complete agreement for 10 of 12 clinical isolates with elevated echinocandin MICs, supporting the potential feasibility of pyrosequencing to detect mutations within diploid fungi.
authors.affiliation: University of Texas at Austin College of Pharmacy, Austin, Texas, USA. wiederholdn@uthscsa.edu
authors.forename: Nathan P
authors.initials: NP
authors.lastname: Wiederhold
authors.forename: Jodi L
authors.initials: JL
authors.lastname: Grabinski
authors.forename: Guillermo
authors.initials: G
authors.lastname: Garcia-Effron
authors.forename: David S
authors.initials: DS
authors.lastname: Perlin
authors.forename: Samuel A
authors.initials: SA
authors.lastname: Lee
mesh_terms: D000077612:Anidulafungin; D000935:Antifungal Agents / Q000494:pharmacology*; D001483:Base Sequence; D002176:Candida albicans / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics* / Q000302:isolation & purification; D002177:Candidiasis / Q000188:drug therapy / Q000382:microbiology; D000077336:Caspofungin; D004252:DNA Mutational Analysis / Q000379:methods*; D004271:DNA, Fungal / Q000235:genetics; D025141:Drug Resistance, Fungal / Q000235:genetics; D054714:Echinocandins / Q000494:pharmacology*; D005800:Genes, Fungal; D005964:Glucosyltransferases / Q000235:genetics*; D006801:Humans; D055666:Lipopeptides / Q000494:pharmacology; D000077551:Micafungin; D017354:Point Mutation
chemical_list: D000935:Antifungal Agents; D004271:DNA, Fungal; D054714:Echinocandins; D055666:Lipopeptides; D000077612:Anidulafungin; D005964:Glucosyltransferases; C020570:1,3-beta-glucan synthase; D000077336:Caspofungin; D000077551:Micafungin
references.citation: Pharmacotherapy. 2006 Jun;26(6):877-80
references.pmid: 16716141
references.citation: Antimicrob Agents Chemother. 2007 Nov;51(11):4214-6
references.pmid: 17785512
references.citation: N Engl J Med. 2007 Jun 14;356(24):2472-82
references.pmid: 17568028
references.citation: Antimicrob Agents Chemother. 2004 Apr;48(4):1382-3
references.pmid: 15047549
references.citation: Antimicrob Agents Chemother. 2007 May;51(5):1876-8
references.pmid: 17325225
references.citation: Antimicrob Agents Chemother. 2005 Aug;49(8):3264-73
references.pmid: 16048935
references.citation: Antimicrob Agents Chemother. 2005 Feb;49(2):767-9
references.pmid: 15673762
references.citation: J Clin Microbiol. 2005 Feb;43(2):906-8
references.pmid: 15695702
references.citation: J Clin Microbiol. 2008 Aug;46(8):2620-9
references.pmid: 18579718
references.citation: Antimicrob Agents Chemother. 2007 Jun;51(6):2253-6
references.pmid: 17420211
references.citation: Lancet. 2007 May 5;369(9572):1519-1527
references.pmid: 17482982
references.citation: N Engl J Med. 2002 Dec 19;347(25):2020-9
references.pmid: 12490683
references.citation: Clin Infect Dis. 2006 Apr 1;42(7):938-44
references.pmid: 16511756
references.citation: Antimicrob Agents Chemother. 2006 Jun;50(6):2058-63
references.pmid: 16723566
references.citation: Electrophoresis. 2006 Aug;27(15):3042-7
references.pmid: 16800029
references.citation: Clin Infect Dis. 2007 Oct 1;45(7):883-93
references.pmid: 17806055
references.citation: J Clin Microbiol. 2004 Oct;42(10):4788-95
references.pmid: 15472342
references.citation: Med Mycol. 2005 Sep;43(6):559-64
references.pmid: 16320498
references.citation: Breast Cancer Res Treat. 2006 Jan;95(1):13-6
references.pmid: 16317586
references.citation: Antimicrob Agents Chemother. 2006 Jul;50(7):2522-4
references.pmid: 16801435
references.citation: Clin Chim Acta. 2006 Jan;363(1-2):83-94
references.pmid: 16165119
references.citation: Antimicrob Agents Chemother. 2007 May;51(5):1616-20
references.pmid: 17307976